Carmeseal-MD

Carmeseal-MD is a subcutaneously administered formulation of Poloxamer 188 NF (P-188 NF), a nonionic triblock copolymer being developed as a first-in-class membrane sealant for diseases characterized by sarcolemmal membrane instability, particularly Duchenne muscular dystrophy (DMD). By inserting into and “sealing” microscopic tears in dystrophic muscle cell membranes, Carmeseal-MD acts as a molecular band-aid that prevents pathological calcium influx, thereby reducing downstream necrosis, fibrosis, and contractile dysfunction in skeletal, diaphragmatic, and cardiac muscle.[1][3][5][7][9][11][17] In preclinical DMD and heart failure models, once-daily low-dose administration improved cardiac efficiency, diaphragmatic performance, and limb muscle protection, and early clinical experience in non‑ambulatory DMD patients has shown biomarker improvements and good tolerability, supporting its development as a disease‑modifying therapy independent of specific dystrophin mutation.[1][2][3][5][7][9][11][17]

Brand names

Carmeseal-MD

Other names

Carmeseal